Equillium (EQ) Return on Capital Employed (2018 - 2026)
Equillium (EQ) posted quarterly Return on Capital Employed of 46.16% for Q1 2026, up 4845.0% year-over-year from 0.93% in Q1 2025, and up 40.9% quarter-over-quarter from 78.1% in Q4 2025.
Equillium (EQ) Return on Capital Employed (2018 - 2026) Analysis & Trends
Equillium (EQ) has reported Return on Capital Employed for 9 consecutive years, with 46.16% the latest figure, recorded in Q1 2026.
- In Q1 2026, Return on Capital Employed rose 4845.0% year-over-year to 46.16%; the TTM figure through Mar 2026 stood at 46.16% (up 4845.0% YoY), while the FY2025 annual figure was 91.56%, down 6549.0% from the prior year.
- Return on Capital Employed grew to 46.16% in Q1 2026 per EQ's latest filing, from 78.1% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 24.53% in Q3 2024 and bottomed at 1632.72% in Q4 2022.
- Historically, Return on Capital Employed has averaged 244.25% across 5 years, with a median of 78.1% in 2025.
- Annual changes were most pronounced in 2022 — Return on Capital Employed plunged 158550 bps — and 2023, when it jumped 157533 bps.
- Equillium's Return on Capital Employed stood at 1632.72% in 2022, then surged by 96 bps to 57.39% in 2023, then soared by 39 bps to 34.92% in 2024, then slumped by 124 bps to 78.1% in 2025, then jumped by 41 bps to 46.16% in 2026.
- Business Quant data shows EQ's Return on Capital Employed at 46.16% in Q1 2026, 78.1% in Q4 2025, and 119.71% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -55.45% |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.20% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 7.88% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 26.09% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -50.93% |
| 10 | Equillium | 263.86 Mn | 263.86 Mn | - | -33.05% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -33.05% |
| Mar 31, 2026 | -46.16% |
| Dec 31, 2025 | -78.10% |
| Sep 30, 2025 | -119.71% |
| Jun 30, 2025 | -279.33% |
| Mar 31, 2025 | -94.61% |
| Dec 31, 2024 | -34.92% |
| Sep 30, 2024 | -24.53% |
| Jun 30, 2024 | -42.12% |
| Mar 31, 2024 | -53.13% |
| Dec 31, 2023 | -57.39% |
| Sep 30, 2023 | -32.23% |
| Jun 30, 2023 | -47.17% |
| Mar 31, 2023 | -187.38% |
| Dec 31, 2022 | -1,632.72% |
| Sep 30, 2022 | -356.31% |
| Jun 30, 2022 | -904.83% |
| Mar 31, 2022 | -161.55% |
| Dec 31, 2021 | -47.22% |
| Sep 30, 2021 | -41.15% |